Experts discuss ongoing research with CELMoDs in the treatment of patients with multiple myeloma.
Dr. Sagar Lonial explores the emergence of CELMoDs for the treatment of multiple myeloma, explaining their mechanism of targeted protein degradation and its impact on myeloma cell survival. He discusses key agents including iberdomide and mezigdomide, highlights their clinical advantages over traditional IMiDs, and outlines their enhanced immunomodulatory effects and potential to improve patient outcomes.
Gurbakhash Kaur, MD, discusses the exploration of CELMoDs in multiple myeloma care and how they may affect the treatment paradigm.
Gurbakhash Kaur, MD, discusses the potential role of CELMoDs in the multiple myeloma treatment paradigm.
Sagar Lonial, MD, FACP, FASCO, discusses the potential role of CELMoD-based combination approaches in newly diagnosed, transplant-ineligible multiple myeloma.
Rahul Banerjee, MD, FACP, discusses the potential long-term role of CELMoDs in the multiple myeloma treatment paradigm.
Sagar Lonial, MD, FACP, FASCO, discusses findings from the CC-220-MM-001 trial of iberdomide plus daratumumab and dexamethasone in newly diagnosed myeloma.
Rahul Banerjee, MD, FACP, discusses the ongoing investigations of mezigdomide and CELMoDs in multiple myeloma.
Dr Banerjee discussed the potential of CELMoDs for multiple myeloma management, highlighting their superior efficacy and safety compared with IMiDs.
Joshua Richter, MD, elaborates on the best scenarios for certain CELMoD-based treatments for patients with multiple myeloma.
Joshua Richter, MD, discusses the exploration of CELMoDs in the treatment of patients with multiple myeloma.
